# Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00408590** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 37 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **BIOLOGICAL:** carcinoembryonic antigen-expressing measles virus
- **BIOLOGICAL:** oncolytic measles virus encoding thyroidal sodium iodide symporter
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00408590
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-19
- **Primary completion:** 2012-08
- **Final completion:** 2017-11-07
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408590, "Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00408590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*